KFDA - NewsChannel 10 / Amarillo, TX: newschannel10.comAffymax 3Q loss narrows partnership payments

Affymax 3Q loss narrows partnership payments

Posted: Updated:

PALO ALTO, Calif. (AP) - Biotechnology company Affymax Inc. said Wednesday its third-quarter loss narrowed on a boost in payments from its partner Takeda Pharmaceutical on the anemia drug candidate Hematide.

The company lost $18.4 million, or 97 cents per share, compared with a loss of $26.2 million, or $1.72 per share, during the same period a year earlier. Revenue rose 35 percent to $29.2 million from $21.6 million, boosted by its development partnership for Hematide.

Analysts polled by Thomson Reuters expected a loss of $1.23 per share on revenue of $26.1 million.

Operating expenses fell slightly to $47.9 million from $48.1 million.

Affymax has said it plans to ask for Food and Drug Administration approval for Hematide in 2010.

Shares of Affymax fell 2 cents to $20.65 in morning trading.

Copyright 2009 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Weather in the Classroom

Here is where you will find your Weather in the Classroom information.

NewsChannel 10 Tax Guide

Click here to find daily tax tips, forms, rules, and FAQ's. Brought to you by Jackson-Hewitt.

>Video, Stories and much more.

Find out what and when programs come on NewsChannel 10.

Entertainment

Click here to find out what's happening in Music, Movies, Television, and Video Games

Link to the Official Texas Lottery website to see if you have won!

Click here to view a large selection of online games and downloads.

Powered by WorldNow
All content © Copyright 2000 - 2010 WorldNow and KFDA. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.